Alba Irisarri
Av. Joan XXIII, 27-31
Barcelona, CT, Spain
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Structure-based virtual screening, in vitro and in silico analysis identified novel potent m6A demethylase FTO inhibitors as promising neurotherapeutic agents.
Journal: European journal of medicinal chemistry
Published: March 30, 2026
Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.
Journal: International journal of molecular sciences
Published: January 30, 2026
First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 06, 2025
FTO inhibition mitigates high-fat diet-induced metabolic disturbances and cognitive decline in SAMP8 mice.
Journal: Molecular medicine (Cambridge, Mass.)
Published: November 01, 2024
G9a an Epigenetic Therapeutic Strategy for Neurodegenerative Conditions: From Target Discovery to Clinical Trials.
Journal: Medicinal research reviews
Published: January 17, 2024
Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I2 receptor ligands.
Journal: Bioorganic chemistry
Published: July 02, 2023
Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer's Disease Neurodegeneration.
Journal: International journal of molecular sciences
Published: October 28, 2022
Cognitive Decline and BPSD Are Concomitant with Autophagic and Synaptic Deficits Associated with G9a Alterations in Aged SAMP8 Mice.
Journal: Cells
Published: July 12, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026